USFDA accepts Biocon-Mylan#39;s Avastin biosimilar application for review

USFDA accepts Biocon-Mylan#39;s Avastin biosimilar application for review The target action date (TAD) or goal date for deciding on approval was set at December 27, 2020.

No comments:

Post a Comment